IN THIS EPISODE - What a peptide actually is, and why your GLP-1 is NOT the same thing as BPC-157 or TB-500 - The seven peptides the FDA is reviewing: BPC-157, KPV, TB-500 (the "Wolverine complex"), MOTS-c, DSIP, Semax, and Epitalon - The "funding gap" why peptides that can't be patented never get human clinical trials - Six things the FDA worries about in an unlabeled vial, from identity and purity to the cancer/angiogenesis risk - The two questions that tell you if a peptide provider is legitimate (503A/B pharmacies and third-party certificates of analysis) ABOUT THE GUEST Tanna Donalson is a Physician Assistant and Owner of Redbud Medical in Denver Colorado
Taken in accordance with instructions on the label and an appropriate diet and exercise regimen, GLP-1s are effective at lowering a persons weight
As research continues to expand, this peptide carries promise for future clinical applications
Lembo A, Camilleri M
Initially, it was approved for the treatment of type 2 diabetes, where it proved highly effective in improving blood sugar control
